Hennion & Walsh Asset Management, Inc. Chemo Centryx, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

$2.1 Billion
Q4 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$22.17 - $51.8 $26,559 - $62,056	-1,198 Reduced 3.24%	35,740 $1.85 Million
Q2 2022 Jul 19, 2022	SELL	$15.36 - $27.51 $473,886 - $848,738	-30,852 Reduced 45.51%	36,938 $915,000
Q1 2022 Apr 26, 2022	BUY	$22.22 - $39.12 $254,352 - $447,806	11,447 Added 20.32%	67,790 $1.7 Million
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $329,149 - $725,274	17,908 Added 46.59%	56,343 $2.05 Million
Q3 2021 Nov 12, 2021	SELL	$13.18 - $19.83 $25,081 - $37,736	-1,903 Reduced 4.72%	38,435 $657,000
Q2 2021 Aug 13, 2021	BUY	$9.59 - $50.88 $14,480 - $76,828	1,510 Added 3.89%	40,338 $540,000
Q1 2021 May 17, 2021	BUY	$49.53 - $68.4 $1.92 Million - $2.66 Million	38,828 New	38,828 $1.99 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.